Fundraising Fox

/Companies

CND Life Sciences

Scottsdale, US · Founded 2017 · Delaware corporation · 3 known investors

Find your way into CND Life Sciences

Sign up to see every warm intro you have to CND Life Sciences

Paths you didn't know you had: your email and LinkedIn already hold routes to the CND Life Sciences team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

CND Life Sciences develops skin-based neurodiagnostic tests, including a test to detect abnormal alpha-synuclein in skin biopsies to help physicians diagnose Parkinson's disease and related synucleinopathies. It operates a CLIA-certified and CAP-accredited pathology lab serving clinicians and patients.

Biotech Digital Health Medical Devices

Founders & leadership

CND Life Sciences was founded in 2017 by Todd Levine.

TL

Todd Levine

Todd Levine Founder · Chief Medical OfficerTodd Levine is a clinical neurologist with over 30 years of experience, including 15+ years developing diagnostic tests for neurological diseases, and served as Director of Preventative Neurology at HonorHealth before joining CND Life Sciences.

RJ

Richard J. Morello

Richard J. MorelloExecutive

PH

Peter Harris

Peter Harris DirectorPeter Harris is an executive officer and director at CND Life Sciences, which develops skin-based neurodiagnostic tests to help physicians diagnose Parkinson's disease and related conditions.

CG

Christopher GibbonsNamed on SEC filing

Board

JS

Jack SeaverBoard director

EC

Enrique CarrazanaBoard director

RF

Roy FreemanBoard director

Investors · 3

BlueStone Venture Partnerslisted by BlueStone Venture PartnersTucson · $250K – $1M

Top Corner Capitallisted by Top Corner CapitalBurlingame

MBX CapitalreportedClaymont · $250K – $2.5M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$30M disclosed across 7 rounds · 2021–2026

▶$6.3MraisedAug 2026 · 14 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Richard J. MorelloExecutive Officer, Director
Todd LevineExecutive Officer, Director
Peter HarrisExecutive Officer, Director
Enrique CarrazanaDirector
Christopher GibbonsDirector
Jack SeaverDirector

Offering amount: $6.3M
Amount sold: $6.3M
Minimum investment: $25K
First sale: Jun 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$8.6MraisedMay 2025 · 38 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Richard J. MorelloExecutive Officer, Director
Todd LevineExecutive Officer, Director
Jack SeaverDirector
Peter HarrisExecutive Officer, Director
Enrique CarrazanaDirector
Christopher GibbonsDirector

Offering amount: $9M
Amount sold: $8.6M
Minimum investment: $25K
Sales commissions: $36K
Placement agents: Finalis Securities
First sale: Feb 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedMar 2024 · 22 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Peter HarrisDirector
Richard J. MorelloExecutive Officer, Director
Enrique CarrazanaDirector
Todd LevineExecutive Officer, Director

Offering amount: $6M
Amount sold: $2M
Minimum investment: $25K
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.5MraisedJul 2023 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Enrique CarrazanaDirector
Richard J. MorelloExecutive Officer, Director
Peter HarrisExecutive Officer, Director
Todd LevineDirector

Offering amount: $1.5M
Amount sold: $1.5M
First sale: Jul 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.5MraisedMar 2023 · 26 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Todd LevineExecutive Officer, Director
Richard J. MorelloExecutive Officer, Director
Peter HarrisExecutive Officer, Director
Enrique CarrazanaDirector

Offering amount: $4.5M
Amount sold: $4.5M
First sale: Sep 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.2MraisedNov 2021 · 22 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Peter HarrisDirector
Enrique CarrazanaDirector
Todd LevineDirector
Richard J. MorelloExecutive Officer, Director
Roy FreemanDirector

Offering amount: $5M
Amount sold: $4.2M
Minimum investment: $50K
First sale: Oct 2021
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.9MraisedApr 2021 · 20 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Roy FreemanDirector
Todd LevineDirector
Peter HarrisDirector
Richard J. MorelloExecutive Officer, Director
Christopher GibbonsDirector

Offering amount: $2.9M
Amount sold: $2.9M
Minimum investment: $50K
First sale: Jan 2021
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies working in the same space as CND Life Sciences.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2022	$2.4M
National Institutes of Health (NIH)National Institutes of Health	Phase II	2022	$2M
National Institutes of Health (NIH)National Institutes of Health	Phase II	2020	$2.4M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

CND Life Sciences Closes Growth Fundingfinsmes.com · Aug 2026

Frequently asked questions

What does CND Life Sciences do?: CND Life Sciences develops skin-based neurodiagnostic tests, including a test to detect abnormal alpha-synuclein in skin biopsies to help physicians diagnose Parkinson's disease and related synucleinopathies. It operates a CLIA-certified and CAP-accredited pathology lab serving clinicians and patients.
Who founded CND Life Sciences?: CND Life Sciences was founded by Todd Levine in 2017.
Who are CND Life Sciences's investors?: CND Life Sciences's investors include BlueStone Venture Partners, Top Corner Capital, MBX Capital.
How much funding has CND Life Sciences raised?: CND Life Sciences has disclosed $30M raised across 7 rounds.
Where is CND Life Sciences headquartered?: CND Life Sciences is headquartered in Scottsdale, US.